OPEN ACCESS Freely available online

Molecular Pathology and Biochemistry

Opinion Article

Post-Translational Modifications in Disease Development

David Kim*

Department of Molecular Biology, Seoul National University, Seoul, South Korea.

ABOVE THE STUDY

Post-Translational Modifications (PTMs) are one of the most critical yet often underappreciated layers of biological regulation, and in my opinion, they represent a central control system through which cellular behavior is rapidly and reversibly tuned. While genomics and transcriptomics provide information about potential biological activity, PTMs determine the actual functional state of proteins. This makes them especially important in disease development, where subtle biochemical changes can dramatically alter cellular fate without requiring changes in gene expression.

At a fundamental level, PTMs involve chemical modifications to proteins after their synthesis. These include phosphorylation, acetylation, methylation, ubiquitination, glycosylation, sumoylation, and lipidation, among others. Each modification can influence protein stability, localization, interaction networks, and enzymatic activity. In my view, PTMs act as a molecular "language" that translates cellular signals into functional outcomes, enabling rapid adaptation to environmental and physiological changes.

Phosphorylation is perhaps the most extensively studied PTM and plays a dominant role in signal transduction pathways. Kinases and phosphatases dynamically regulate phosphorylation states of proteins involved in growth, metabolism, and apoptosis. Dysregulation of these processes is a hallmark of many diseases, particularly cancer. Oncogenic mutations often lead to constitutive activation of kinase signaling pathways, resulting in uncontrolled proliferation and survival. In my opinion, cancer can be largely viewed as a disease of disrupted phosphorylation networks, where signaling precision is replaced by persistent activation.

Ubiquitination is another critical PTM that regulates protein degradation via the proteasome system. By tagging proteins for destruction, ubiquitination maintains protein quality control and regulates the abundance of key signaling molecules. In disease states, abnormalities in ubiquitin ligases or deubiquitinating enzymes can lead to either excessive degradation or pathological accumulation of proteins. Neurodegenerative diseases such as Parkinson's and Alzheimer's are strongly associated with impaired ubiquitin–proteasome function, leading to toxic protein aggregation.

Acetylation and methylation of proteins, particularly histones, play central roles in epigenetic regulation. These modifications influence chromatin structure and gene expression patterns without altering sequences. In cancer and other chronic diseases, abnormal histone modifications can lead to inappropriate activation or silencing of genes involved in cell cycle regulation, DNA repair, and apoptosis. In my view, PTM-driven epigenetic reprogramming is one of the key mechanisms by which environmental and metabolic factors influence long-term disease risk.

Glycosylation, as a post-translational modification, is particularly important in cell-cell communication and immune recognition. Altered glycosylation patterns are frequently observed in cancer, inflammatory diseases, and congenital disorders. These changes can affect receptor function, antibody activity, and cell adhesion. Importantly, glycosylation is highly dynamic and context-dependent, making it a sensitive indicator of physiological and pathological states.

Sumoylation and other less-studied PTMs also contribute to disease mechanisms by regulating nuclear transport, transcriptional activity, and stress responses. These modifications often act in concert, creating complex regulatory networks rather than isolated effects. In my opinion, the combinatorial nature of PTMs is what gives them such powerful regulatory capacity, but also makes them difficult to study in isolation.

A key feature of PTMs is their reversibility, which allows cells to rapidly respond to internal and external signals. However, in disease states, this balance between modification and demodification is often disrupted. For example, oxidative stress can aberrantly modify cysteine residues on proteins, altering their function and contributing to cellular damage. Similarly, chronic inflammation can sustain abnormal PTM patterns that reinforce pathological signaling loops.

From a systems biology perspective, PTMs act as integration points for multiple signaling pathways. They connect metabolic

Correspondence to David Kim. Department of Molecular Biology, Seoul National University, Seoul, South Korea. E-mail: david.kim@snu.ac.kr

Received: 20-Aug-2025, Manuscript No. JMPB-25-41770; **Editor assigned:** 22-Aug-2025, PreQC No. JMPB-25-41770 (PQ); **Reviewed:** 05-Sep-2025, QC No. JMPB-25-41770; **Revised:** 12-Sep-2025, Manuscript No. JMPB-25-41770 (R); **Published:** 19-Sep-2025. DOI: 10.35248/jmpb.25.6.231.

Citation: Kim D (2025 Post-Translational Modifications in Disease Development. J Mol Pathol Biochem.6:231.

status, environmental stress, and genetic regulation into a unified functional output. In my view, this integrative role makes PTMs one of the most important but least fully understood layers of cellular regulation in disease biology.

Therapeutically, targeting PTM-regulating enzymes has already shown significant success. Kinase inhibitors in cancer therapy, histone deacetylase inhibitors in epigenetic diseases, and proteasome inhibitors in hematological malignancies demonstrate the clinical relevance of PTM modulation. However, specificity remains a major challenge, as these enzymes often regulate multiple substrates and pathways.

In conclusion, post-translational modifications are fundamental regulators of protein function and play a central role in disease development. In my opinion, they represent a dynamic regulatory layer that bridges genotype and phenotype, making them essential for understanding complex disease mechanisms. Future advances in proteomics, mass spectrometry, and systems biology are likely to reveal even deeper insights into PTM networks, ultimately enabling more precise and targeted therapeutic strategies for a wide range of diseases.